PREPARATION: Effects of Preoperative Multidisciplinary Team Meetings for High-risk, Adult, Noncardiac Surgical Patients

Sponsor
Rijnstate Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05703230
Collaborator
ZonMw: The Netherlands Organisation for Health Research and Development (Other), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Other), University of Twente (Other), University Medical Center Groningen (Other), Maastricht University Medical Center (Other), Leiden University Medical Center (Other)
1,200
14
2
36
85.7
2.4

Study Details

Study Description

Brief Summary

The current multicenter stepped wedge randomized cluster trial study aims to assess whether implementation of preoperative multidisciplinary team (MDT) discussions is (cost)effective for high risk noncardiac surgical patients.

The main questions to answer are:
  • Primary question: Does implementation of preoperative multidisciplinary team discussions for high risk noncardiac surgical patients diminish serious adverse events as compared to care as usual at six months postoperatively or six months after multidisciplinary team discussion in case of nonsurgical treatment?

  • Secondary questions: Does implementation of preoperative multidisciplinary team discussion for high risk noncardiac surgical patients improve disability, survival, functional outcome, quality of life and cost-effectiveness as compared to care as usual at six months postoperatively or six months after multidisciplinary team discussion in case of nonsurgical treatment?

Participants will be asked to answer questionnaires at baseline, 3, 6,9 and 12 months postoperatively or post MDT discussion.

Patients for whom no structured preoperative multidisciplinary discussion is installed yet (care as usual) will be compared with patients for whom a structured preoperative multidisciplinary discussion is performed (intervention).

The study will be performed in hospitals that have no established preoperative MDT meeting at the start of the study.

Detailed Description

Due to the increase in life expectancy and improved care for patients suffering from a chronic disease, the number of complex patients requiring a surgical intervention is increasing. It is important to balance the potential benefits of this surgical treatment against the risk of permanent loss of functional capacity and quality of life due to complications. European and US guidelines on perioperative care all recommend preoperative multidisciplinary team meetings for high-risk noncardiac surgical patients. However, the evidence underlying a benefit of a preoperative MDT meeting is absent and recommendations are based on expert opinion. Moreover, considerable practice variation is currently present.

This study will assess the efficacy of implementation of a preoperative structured multidisciplinary team (sMDT) meeting to optimize perioperative management for high risk noncardiac surgical patients.

The hypothesis is that implementation of preoperative sMDT meetings for high risk noncardiac surgical patients results in less serious adverse events, is more cost-effective, and improves quality of life and functional outcome at six months, compared to preoperative care as usual (control).

A preoperative structured Multidisciplinary Team (sMDT) meeting for high risk noncardiac surgical patients will be implemented in each participating center (n=14) throughout the study. In the sMDT meeting, patients' treatment plan and alternatives will be discussed by the anesthesiologist, surgical specialist and other relevant consultants or (specialized) nurses.

The primary outcome is Serious adverse events (SAEs) according to the Clavien Dindo classification grade 3 or more, at 6 months following surgery or following the preoperative sMDT meeting in case of nonsurgical management. Secondary outcomes are: functional outcome (12-item WHO Disability Assessment Schedule), survival, quality of life (WHOQOL BREF), patients' regret (including interview at 6 months), societal costs (iMCQ and iPCQ, Electronic Medical Record (EMR) data, EQ5D-5L), alterations in perioperative management and sMDT performance (MDT-MOT), and facilitators and barriers (using structured interviews health care professionals). Most secondary outcomes will be assessed at baseline, 30 days, 3, 6 and 12 months.

Subgroup analyses will take place for e.g. age groups (approximate quintiles), patient sex, size of hospital, intent of surgery, BMI categories (underweight, normal, overweight, obese, ≥super obese), ASA physical status, frailty, MET score, smoking behavior, alcohol use, comorbidity index score, planned postoperative destination, educational attainment, and employment status.

For detailed description, see below.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1200 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
cross-sectional stepped wedge cluster randomized trialcross-sectional stepped wedge cluster randomized trial
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Is a Preoperative Multidisciplinary Team Meeting (Cost) Effective in Optimizing Noncardiac Surgical Patient Management: The PREPARATION Study
Actual Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Apr 30, 2025
Anticipated Study Completion Date :
Oct 31, 2025

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Preoperative care as usual

Patients undergoing preoperative care as usual, which does not include a structured preoperative multidisciplinary team meeting (no sMDT meeting)

Active Comparator: Structured preoperative multidisciplinary team meeting

Patients are discussed preoperatively in a structured preoperative multidisciplinary team meeting

Other: Structured preoperative multidisciplinary team meeting
The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline: Is the proposed surgical intervention appropriate care for the patient? Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient? Should the patient's condition be optimized before undergoing the proposed surgical intervention?

Outcome Measures

Primary Outcome Measures

  1. Serious Adverse Events (SAEs) [6 months]

    Serious adverse events (SAEs), defined as: Grade 3 or more on the Clavien Dindo classification following surgical intervention, or non-operative SAEs will be graded accordingly i.e., events necessitating hospital admission, surgical intervention, single or multi-organ failure, or death.

Secondary Outcome Measures

  1. Disability status [12 months]

    The disability status of the patient, measured by the 12-item WHO disability Assessment Schedule 2.0 (WHODAS 2.0). The WHODAS 2.0 results in a metric ranging from 0 to 100 ( where 0 = no disability; 100 = full disability).

  2. Patient experienced quality of life [12 months]

    Quality of life of the patient assessed by the abbreviated World Health Organization Quality of Life (WHOQOL BREF). The WHOQOL BREF results in a percentage of 0 to 100. The higher the percentage (to 100), the better the quality of life of the participant.

  3. Regret of decision [12 months]

    Patients regret of decision measured by a modification of the Decision Regret Scale at 3, 6 and 12 months and qualitative interviews with several patients at 6 months. The decision regret scale is a 5-item questionnaire, scoring statements 1 (strongly agree) to 5 (strongly disagree). Final scoring consists of reversing the scores of the two negatively phrased items, then taking the mean of the five items. Last, the mean is converted to a score ranging from 0 to 100 by subtracting 1 and multiplying by 25. A higher score may indicate greater patient regret about their made treatment decisions. The scale was modified by adding a question asking by whom the decision was made. This question is not part of the previously described scoring of the 5-item decision regret scale.

  4. Societal costs measured by a patient cost questionnaire [12 months]

    Societal costs as measured by a cost questionnaire at baseline, 3 and 12 months, including items of the iMTA (Institute for Medical Technology Assessment) Medical Consumption Questionnaire (iMCQ) and iMTA Productivity Cost Questionnaire (iPCQ) with a recall period of 3 months.

  5. Hospital costs as a component of societal costs [12 months]

    Hospital costs based on electronic medical record (EMR) patient data, as a component of societal costs. Measured at baseline (hospital costs over a period of 3 months prior to preoperative screening) and measured during 12 months follow up.

  6. Quality-adjusted life years as a component of societal costs [12 months]

    Quality-adjusted life years (QALYs) measured by the EQ-5D-5L at baseline, 3 and 12 months, as a component of societal costs.

  7. Patients' desired outcome [baseline]

    Patients' desired outcome will be assessed using the Outcome Prioritization Tool (OPT) at baseline (pre-operative assessment).

  8. Survival [30 days, 6 months, and 1 year postoperatively]

    Survival at 30 days, 6 months, and 1 year postoperatively

  9. Adverse events [30 days, 6 months, and 1 year postoperatively]

    Adverse events at 30 days, 6 months, and 1 year postoperatively

  10. Surgical Outcome Risk Tool (SORT) [baseline]

    Calculating an estimate of the patients' risk of death within 30 days of an operation.

  11. Revised Cardiac Risk Index for Pre-Operative Risk (RCRI) [baseline]

    The RCRI estimates patients' risk of cardiac complications after noncardiac surgery. The index is constructed by 6 items. The 6 items are scored yes (+1) or no (0), adding up to a minimum score of 0 and a maximum score of 6. The score is categorised into 4 categories (0, 1, 2, ≥3) and converted to "risk of major cardiac event (95% CI)" defined as death, myocardial infarction, or cardiac arrest at 30 days after noncardiac surgery.

  12. American College of Surgeons Surgical Risk Calculator (ACS-NSQIP (American College of Surgeons National Surgical Quality Improvement Program)) [baseline]

    Estimates patients' risk of postoperative complications.

  13. Clinical Frailty Scale (CFS) [baseline]

    A judgement-based frailty tool that evaluates specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill).

  14. Metabolic Equivalent of Task (MET) [baseline]

    Reflecting the amount of energy used by the body during physical activity.

  15. The number of alterations in perioperative management decided by the sMDT. [baseline]

    The number of alterations in perioperative management decided by the sMDT (19, 20). Examples for alterations are (but not limited to) changes in; type of anaesthesia, type of surgery, planned postoperative intensive care admission, cancellation of surgery, additional medication or diagnostics.

  16. The nature of alterations in perioperative management decided by the sMDT. [baseline]

    The nature of alterations in perioperative management decided by the sMDT (19, 20). Examples for alterations are (but not limited to) changes in; type of anaesthesia, type of surgery, planned postoperative intensive care admission, cancellation of surgery, additional medication or diagnostics.

  17. The number of different medical specialties invited to participate in the sMDT meeting [baseline]

    The number of different medical specialties present during the sMDT meeting in order to describe the multidisciplinary attendance of the sMDT meetings.

  18. The number of different medical specialties present during the sMDT meeting [baseline]

    The number of different medical specialties present during the sMDT meeting in order to describe the multidisciplinary attendance of the sMDT meetings.

  19. The function of attending professionals at the sMDT meeting. [baseline]

    The function of attending professionals at the sMDT meeting in order to describe the multidisciplinary attendance of the sMDT meetings.

  20. Number of sMDT discussions per site [through study completion, 3 years]

    Number of sMDT discussions per site

Other Outcome Measures

  1. Performance of sMDTs using an MDT-Meeting Observational Tool (MDT-MOT) [6 months]

    In a subset of patients: Performance of sMDTs using an MDT-Meeting Observational Tool (MDT-MOT).(21) In the MDT-MOT 10 observable teamwork domains are rated on a 5-point rating scale, using descriptive anchors for the extremes and midpoint of the scale. A score of '5' represents optimal effectiveness, calibrated against recommendations within 'The Characteristics of an Effective MDT' (by the National Cancer Action Team). A score of '3' represents effectiveness that exhibits some degree of agreement with the optimum, but not consistently, and a score of '1' represents no or little agreement with the defined optimum. Scores of '2' and '4' are included in the tool but not defined to allow observers the freedom to gradate their assessment.

  2. Facilitators and barriers to organize preoperative sMDT meetings [6 months]

    Facilitators and barriers to organize preoperative sMDT meetings are evaluated using structured interviews with health care professionals from all different medical specialties.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years of age or older; and

  • American Society of Anesthesiology Physical Status (ASA-PS) score is 3 or more; and

  • Clinical Frailty Scale score is 4 or more; and

  • Patient is planned for elective or semi-elective noncardiac surgery; and

  • As stated by the Dutch perioperative guideline:

  • Doubt by the surgeon or anesthesiologist (or other discipline) regarding harm-benefit ratio of the surgical procedure; or

  • Doubt if the correct measures were taken to limit the perioperative risk as much as possible; or

  • Doubt if the patient agrees with the surgery or the anesthesiologic treatment and expected risks.

Exclusion Criteria:
  • no informed consent

  • unable to communicate with patient (either directly or through third party)

  • emergency surgery

  • Proposed surgical intervention for which a structured preoperative multidisciplinary team meeting, similar to the current study intervention, already exists in this respective hospital at the start of the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stichting Jeroen Bosch Ziekenhuis 's-Hertogenbosch Netherlands 5223GZ
2 Stichting Meander Medisch Centrum Amersfoort Netherlands 3817TZ
3 Stichting OLVG Amsterdam Netherlands 1091
4 Gelre Ziekenhuis Apeldoorn Netherlands 7334DZ
5 Stichting Albert Schweitzer Ziekenhuis Dordrecht Netherlands 3318AT
6 Groene Hart Ziekenhuis Gouda Netherlands 2803HH
7 Universitair Medisch Centrum Groningen Groningen Netherlands 9713GZ
8 Zuyderland Medisch Centrum Heerlen Netherlands 6419PC
9 Maastricht Universitair Medisch Centrum Maastricht Netherlands 6229HX
10 Stichting Nijmeegs Interconfessioneel Ziekenhuis Canisius Wilhelmina Nijmegen Netherlands 6532SZ
11 Stichting Bravis Ziekenhuis Roosendaal Netherlands 4708AE
12 Stichting Protestants Christelijk Ziekenhuis Ikazia Rotterdam Netherlands 3083AN
13 Maxima Medisch Centrum Veldhoven Netherlands 5504DB
14 Zaans Medisch Centrum Zaandam Netherlands 1502DV

Sponsors and Collaborators

  • Rijnstate Hospital
  • ZonMw: The Netherlands Organisation for Health Research and Development
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • University of Twente
  • University Medical Center Groningen
  • Maastricht University Medical Center
  • Leiden University Medical Center

Investigators

  • Principal Investigator: Nick J. Koning, MD PhD DESA, Rijnstate Hospital
  • Study Director: Jacqueline E. Vernooij, MD, MA, Rijnstate Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rijnstate Hospital
ClinicalTrials.gov Identifier:
NCT05703230
Other Study ID Numbers:
  • 2021-1983
First Posted:
Jan 27, 2023
Last Update Posted:
Jan 27, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rijnstate Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 27, 2023